Trial Profile
Effectiveness of Empagliflozin on Cardiac-renal Injury in Patients With Acute ST-segment-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 24 Jul 2018 New trial record